Cohance Lifesciences to invest $18 million across NJ Bio and Aruka Bio
Cohance Lifesciences plans to invest a combined $18 million in NJ Bio and Aruka Bio as it deepens its antibody-drug conjugates, or ADCs, push. The company will invest $13 million to increase its ownership of NJ Bio.
Cohance Lifesciences plans to invest a combined $18 million in NJ Bio and Aruka Bio as the company deepens its push into antibody-drug conjugates, or ADCs, an increasingly important class of targeted cancer treatments.The company will invest $13 million to increase its ownership of NJ Bio and anoth…